Update: Personalized diagnostics and therapies for pediatric cancer patients;Update zur personalisierten Diagnostik und Behandlung krebskranker Kinder

Klinische Padiatrie

Volumn 225, Issue 3, 2013, Pages 107-109

  Eggert, Angelika ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER PATIENT; CHILDHOOD CANCER; HUMAN; PERSONALIZED MEDICINE; REVIEW;

ADOLESCENT; CHILD; DATABASES, FACTUAL; DATABASES, GENETIC; ELECTRONIC HEALTH RECORDS; GENETIC MARKERS; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; PROGNOSIS;

EID: 84878402281     PISSN: 03008630     EISSN: 14393824     Source Type: Journal    
DOI: 10.1055/s-0033-1347183     Document Type: Review

References (46)

1. Blackmore C., Coppes M. J., Narendran A. Candidate genes and potential targets for therapeutics in Wilms' tumour. Clin Transl Oncol: 2010; 12 597 605
2. Bochennek K., Esser R., Lehrnbecher T. et al. Impact of minimal residual disease detection prior to autologous stem cell transplantation for post-transplant outcome in high risk neuroblastoma. Klin Padiatr: 2012; 224 139 142
3. Broadhead M. L., Clark J. C., Myers D. E. et al. The molecular pathogenesis of osteosarcoma: a review. Sarcoma: 2011; doi: 10.1155/2011 959248
4. Corbacioglu S. Early phase clinical trials in pediatric hematology and oncology. Klin Padiatr: 2012; 224 197 200
5. Creutzig U., Henze G., Bielack S. et al. Krebserkrankungen im Kindesalter. Erfolg durch einheitliche Therapiekonzepte seit 25 Jahren. Dtsch Ärzteblatt: 2003; 100 A842 A852
6. De Preter K., Mestdagh P., Vermeulen J. et al. miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples. Clin Cancer Res: 2011; 17 7684 7692
7. De Preter K., Vermeulen J., Brors B. et al. Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature. Clin Cancer Res: 2010; 16 1532 1541
8. Druker B. J., Talpaz M., Resta D. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med: 2001; 344 1031 1037 (Pubitemid 32267972)
9. Fischer M., Bauer T., Oberthür A. et al. Integrated genomic profiling identifies two distinct molecular subtypes with divergent outcome in neuroblastoma with loss of chromosome 11q. Oncogene: 2010; 29 865 875
10. Fischer M., Spitz R., Oberthür A. et al. Risk estimation of neuroblastoma patients using molecular markers. Klin Padiatr: 2008; 220 137 146 (Pubitemid 351758156)
11. Grunewald T. G., Greulich N., Kontny U. et al. Targeted therapeutics in treatment of children and young adults with solid tumors: an expert survey and review of the literature. Klin Padiatr: 2012; 224 124 131
12. Gustafson W. C., Matthay KK. Progress towards personalized therapeutics: biologic- and risk-directed therapy for neuroblastoma. Expert Rev Neurother: 2011; 11 1411 1423
13. Haase R., Elsner K., Merkel N. et al. High dose methotrexate treatment in childhood ALL: pilot study on the impact of the MTHFR 677C>T and 1298 A>C polymorphisms on MTX-related toxicity. Klin Padiatr: 2012; 224 156 159
14. Hennes E., Zahn S., Lopes L. F. et al. Molecular genetic analysis of bilateral ovarian germ cell tumors. Klin Padiatr: 2012; 224 359 365
15. Heukamp L. C., Thor T., Schramm A. et al. Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. Science Translat Med: 2012; 4 141ra91
16. Jain S., Xu R., Prieto V. G. et al. Molecular classification of soft tissue sarcomas and its clinical applications. Int J Clin Exp Pathol: 2010; 3 416 428
17. Janoueix-Lerosey I., Schleiermacher G., Michels E. et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol: 2009; 27 1026 1033
18. Jones D. T., Jäger N., Kool M. et al. Dissecting the genomic complexity underlying medulloblastoma. Nature: 2012; 488 100 105
19. Kool M., Korshunov A., Remke M. et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol: 2012; 123 473 484
20. Lawrenz B., Henes M., Neunhoeffer E. et al. Fertility preservation in girls and adolescents before chemotherapy and radiation - review of the literature. Klin Padiatr: 2011; 223 126 130
21. Maris J. M. Recent advances in neuroblastoma. N Engl J Med: 2010; 362 2202 2211
22. Molenaar J. J., Domingo-Fernández R., Ebus M. E. et al. LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet: 2012; 44 1199 1206
23. Northcott P. A., Jones D. T., Kool M. et al. Medulloblastomics: the end of the beginning. Nat Rev Cancer: 2012; 12 818 834
24. Northcott P. A., Korshunov A., Pfister S. M. et al. The clinical implications of medulloblastoma subgroups. Nat Rev Neurol: 2012; 8 340 351
25. Northcott P. A., Korshunov A., Witt H. et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol: 2011; 29 1408 1414
26. Northcott P. A., Shih D. J., Peacock J. et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature: 2012; 488 49 56
27. Oberthuer A., Berthold F., Warnat P. et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol: 2006; 24 5070 5078 (Pubitemid 46631411)
28. Oberthuer A., Hero B., Berthold F. et al. Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol: 2010; 28 3506 3515
29. Ora I., Eggert A. Progress in treatment and risk stratification of neuroblastoma: impact on future clinical and basic research. Semin Cancer Biol: 2011; 21 217 228
30. Park J. R., Eggert A., Caron H. Neuroblastoma: biology, prognosis, and treatment. Pediatr Clin North Am.: 2008; 55 97 120 (Pubitemid 351173188)
31. Pegram M. D., Lipton A., Hayes D. F. et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol: 1998; 16 2659 2671 (Pubitemid 28363029)
32. Potratz J., Jürgens H., Craft A. et al. Ewing sarcoma: biology-based therapeutic perspectives. Pediatr Hematol Oncol: 2012; 29 12 27
33. Pugh T. J., Weeraratne S. D., Archer T. C. et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature: 2012; 488 106 110
34. Rausch T., Jones D. T., Zapatka M. et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell: 2012; 148 59 71
35. Reinhardt D., Von Neuhoff C., Sander A. et al. Genetic prognostic factors in childhood acute myeloid leukemia. Klin Padiatr: 2012; 224 372 376
36. Rossig C., Juergens H. Aetiology of childhood acute leukaemias: current status of knowledge. Radiat Prot Dosimetry: 2008; 132 114 118
37. Royer-Pokora B., Graf N. Wilms tumors arising at young age: a genetic basis to distinguish subgroups for individualized therapy. J Clin Oncol: 2011; 29 e485 e486
38. Schramm A., Schulte J. H., Klein-Hitpass L. et al. Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. Oncogene: 2005; 24 7902 7912 (Pubitemid 41715196)
39. Schwartzentruber J., Korshunov A., Liu X. Y. et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature: 2012; 482 226 231
40. Speleman F., De Preter K., Vandesompele J. Neuroblastoma genetics and phenotype: a tale of heterogeneity. Semin Cancer Biol: 2011; 21 238 244
41. Stanulla M., Cario G., Meissner B. et al. Integrating molecular information into treatment of childhood acute lymphoblastic leukemia - a perspective from the BFM Study Group. Blood Cells Mol Dis: 2007; 39 160 163 (Pubitemid 47126931)
42. Taylor M. D., Northcott P. A., Korshunov A. et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol: 2012; 123 465 472
43. Vermeulen J., De Preter K., Naranjo A. et al. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol: 2009; 10 663 671
44. Witt H., Mack S. C., Ryzhova M. et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell: 2011; 20 143 157
45. Witt O., Milde T., Deubzer H. E. et al. Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia. Klin Padiatr: 2012; 224 398 403
46. Wittmann S., Wunder C., Zirn B. et al. New prognostic markers revealed by evaluation of genes correlated with clinical parameters in Wilms tumors. Genes Chromosomes Cancer: 2008; 47 386 395 (Pubitemid 351451793)